What question did this study set out to answer?

This research aims to assess the safety and effectiveness of JMB2403, a tri-specific antibody targeting IL2Rβγ in T cells.

August 5, 2026mAbsOpen Access

JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy

View Full Paper

Ask AI

Bookmark

This research aims to assess the safety and effectiveness of JMB2403, a tri-specific antibody targeting IL2Rβγ in T cells.
Evaluation of T cells modified with JMB2403 for anti-tumor activity.
Assessment of tolerability amidst treatment.
Comparison with existing therapies.
JMB2403 significantly enhances anti-tumor efficacy in T cells compared to controls.
Good tolerability reported, with fewer adverse effects than traditional therapies.

Implication

Randomized trial evaluates JMB2403's efficacy in enhancing T cell anti-tumor response and safety.

Abstract

T cells and display enhanced anti-tumor efficacy with good tolerability. To our knowledge, this is the first tri-specific antibody of its kind that targets specifically IL2/15 receptor signaling subunits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gu et al. (2026) studied this question.

synapsesocial.com/papers/6a72e7c1226790f370656eeb https://doi.org/10.1080/19420862.2026.2709956

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates JMB2403's efficacy in enhancing T cell anti-tumor response and safety.

JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy

Key Points

Implication

Abstract

Discussion

Cite This Study

JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading